Drug intelligence / Profile preview

Zengneng Jiedu Prescription

Development stage: Unknown
Lead developer: Shanghai Tenth People's Hospital
Administration: Oral

Overview

Zengneng Jiedu Prescription is a Traditional Chinese Medicine (TCM) formula developed by the Shanghai Tenth People's Hospital for the treatment of COVID-19. It is designed as an adjunctive therapy to be used alongside standard antiviral treatments, such as Paxlovid (nirmatrelvir/ritonavir), particularly for adult patients with mild to moderate coronavirus infections. The prescription follows the principles of TCM to potentially enhance the body's immune response and facilitate viral clearance. It has been evaluated in clinical trials to assess its safety and efficacy in improving clinical recovery times and reducing viral shedding duration in the context of the SARS-CoV-2 pandemic.

Other names: ZengnengJiedu Prescription增能解毒方

Beyond the preview

Go deeper on Zengneng Jiedu Prescription.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zengneng Jiedu Prescription.

Explore the full profile